SCHEMBL30749153

SCHEMBL30749153

O=Cc1nc(Nc2ccc(Oc3ccccc3)cc2)c2cn[nH]c2n1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
HTR2A P28223 7/20 0.46
HTR2C P28335 6/20 0.46
PDPK1 O15530 1/20 0.45
MKNK1 Q9BUB5 1/20 0.44
PIN1 Q13526 1/20 0.43
ABL1 P00519 1/20 0.43
BCR P11274 1/20 0.43
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
KDR P35968 2/20 0.42
FLT3 P36888 1/20 0.42
TTBK1 Q5TCY1 1/20 0.42
TTBK2 Q6IQ55 1/20 0.42
PDGFRB P09619 1/20 0.41
TEK Q02763 1/20 0.41
PLK4 O00444 1/20 0.40
PAK4 O96013 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749087 0.88 HTR2A (0.48) MAPK1HTR2AHTR2CPDPK1MKNK1
SCHEMBL30749120 0.82 TTBK1 (0.60) TTBK1TTBK2
SCHEMBL30748782 0.81 HTR2C (0.48) MAPK1HTR2AHTR2CPDPK1MKNK1
SCHEMBL30749039 0.80 HTR2C (0.49) MAPK1HTR2AHTR2CPDPK1MKNK1
SCHEMBL30749082 0.71 MAP2K1 (0.56) PIN1KDRTEK
SCHEMBL30748887 0.70 TTBK1 (0.60) TTBK1TTBK2
SCHEMBL13896217 0.68 MAPK1 (0.59) MAPK1HTR2AHTR2CMKNK1PLK4
SCHEMBL30748877 0.68 SCN9A (0.54) PIN1
SCHEMBL3579029 0.68 PIN1 (0.60) PIN1CSNK2A1PAK4
SCHEMBL13896565 0.66 PLK4 (0.61) MAPK1HTR2AHTR2CPLK4PAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAPK1 2929/4885HTR2A 2620/4885HTR2C 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.